Important treatment attributes considered by Japanese patients with advanced Parkinson's disease (aPD)
- Conditions
- Advanced Parkinson's disease (aPD)
- Registration Number
- JPRN-UMIN000051513
- Lead Sponsor
- AbbVie GK.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Not provided
1) Patients with experience in any device-aided therapy (DATs; CSCI, LCIG, or DBS) or FUS 2) Patients with impaired cognitive function (e.g., MMSE under 23, taking medicine for Alzheimer's disease or cognitive impairment (specifically: donepezil HCl, rivastigmine transdermal system, galantamine, galantamine HBr, memantine HCI)), or psychosis (either past history or current) 3) Patients with a diagnosis of atypical or secondary Parkinsonism 4) Patients with visual impairment significant enough that they cannot comply with the study procedures 5) Did not provide consent to participate (and record the interview) 6) Is not willing nor able to comply with procedures required in this protocol 7) Patients who are pregnant 8) Not fluent in Japanese
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The preference weight and the relative importance (%) of the attributes will be identified by the phase 1 interview conducted in this study in Japanese aPD patients.
- Secondary Outcome Measures
Name Time Method The preference weight and the relative importance (%) of each attribute in each patient subgroup.